Long-lasting cross-presentation of tumor antigen in human DC

European Journal of Immunology

Volumn 39, Issue 2, 2009, Pages 380-390

  Faure, Florence ^a,b   Mantegazza, Adriana ^a,b   Sadaka, Charlotte ^a,b   Sedlik, Christine ^a,b   Jotereau, Francine ^c   Amigorena, Sebastian ^a,b  

^a INSERM   (France)

^b INSTITUT CURIE   (France)

^c Team 12   (France)

Author keywords

Cross presentation; CTL; DC; Long peptides; Melanoma associated antigen

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; TUMOR ANTIGEN; HLA ANTIGEN CLASS 1; MART1 ANTIGEN; TUMOR PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SYNTHESIS;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; PEPTIDES;

EID: 60749098288     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200838669     Document Type: Article

References (62)

1. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D. and Levitsky, H. The central role of GD4(+) T cells in the antitumor immune response. J. Exp. Med. 1998, 188: 2357-2368.
2. Rosenberg, S. A., Progress in human tumour immunology and immunotherapy. Nature 2001. 411: 380-384.
3. Boon, T., Coulie, P. G., Van den Eynde, B. J. and van der Bruggen, P., Human T cell responses against melanoma. Annu. Rev. Immunol. 2006. 24: 175-208.
4. Sun, J. C. and Bevan, M. J., Defective CD81T cell memory following acute infection without CD4T cell help. Science 2003. 300: 339-342.
5. Lanzavecchia, A., Immunology. Licence to kill. Nature 1998. 393: 413-414.
6. Mellman, I. and Steinman, R. M., Dendritic cells: Specialized and regulated antigen processing machines. Cell 2001. 106: 255-258.
7. Guermonprez, P. and Amigorena, S., Pathways for antigen cross presentation. Springer Semin. Immunopathol. 2005. 26: 257-271.
8. Bevan, M. J., Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J. Immunol. 1976. 117: 2233-2238.
9. Trinchieri, G., Aden, D. P. and Knowles, B. B., Cell-mediated cytotoxicity to SV40-specific tumour-associated antigens. Nature 1976. 261: 312-314.
10. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994. 264: 961-965.
11. Sigal, L. J., Cron S., Andino, R. and Rock, K. L., Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999. 398: 77-80.
12. + dendritic cells. J. Immunol. 2001. 166: 5327-5330.
13. Jung, S., Unutmaz, D., Wong, P., Sano, G., De los Santos, K., Sparwasser, T. W. S., Vuthoori, S. K. K. et al., in vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002. 17: 211-220.
14. Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C. et al., Differential antigen processing by dendritic cell subsets in vivo. Science 2007. 315: 107-111.
15. Nagata, Y., Ono, S., Matsuo, M., Gnjatia, S., Valmori, D., Ritter, G., Gaffett, W. et al., Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc. Natl. Acad. Sci. USA 2002. 99: 10629-10634.
16. Moron, G., Dadaglio, G. and Leclerc, C., New tools for antigen delivery to the MHC class I pathway. Trends Immunol. 2004. 25: 92-97.
17. Thumann, P., Moc, I., Humrich, J., Berger, T. G., Schultz, E. S., Schuler, G. and Jenne, L., Antigen loading of dendritic cells with whole tumor cell preparations. J. Immunol. Methods 2003. 277: 1-16.
18. + T cell responses against soluble antigens in vivo. J. Exp. Med. 2005. 202: 817-828.
19. Schnurr, M., Chen, Q., Shin, A., Chen, W., Toy, T., Jenderek, C., Green, S. et al., Tumor antigen processing and presentation depend critically on dendritic cell type-and the made of antigen delivery. Blood 2005. 105: 2465-2472.
20. Motellin, S., Mandruzzato, S., Bronte, V., Lise, M. and Nitti, D., Part I: Vaccines for solid tumours. Lancet Oncol. 2004. 5: 681-689.
21. Thery, C., Zitvogel, L. and Amigorena, S., Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002. 2: 569-579.
22. Escudier, B., Dorval, T., Chaput, N., Andre, F., Caby, M. P, Novault, S., Flament, C. et al., Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase I clinical trial. J. Transl. Med. 2005. 3: 10.
23. Gilboa, E., DC-based cancer vaccines. J. Clin. Invest. 2007. 117: 1195-1203.
24. + T cells in a spectrum of human MHC I haplotypes. Proc. Natl. Acad. Sci. USA 2007. 104: 1289-1294
25. Melief, C. J. M., Welters, M. J. P., Löwik, M. J. G., Vloon, A. P. G., Drijfhout, J. W., Valentijn, A. R. P.M., Wafelman, A. R. et al., Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16. Cancer Immun. 2008. 8 (Suppl. 1): 2.
26. Vambutas, A., DeVoti, J., Nouri, M., Drijfhout, J. W., Lipford, G. B. Bonagura, V. R., van der Burg, S. H. and Melief, C. J., Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005. 23: 5271-5280.
27. Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Thery, C., Rescigno, M., Saito, T. et al., Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 1999. 189: 371-380.
28. Ackerman, A. L., Kyritsis, C., Tampe, R. and Cresswell, P., Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat. Immunol. 2005. 6: 107-113.
29. Savina, A., Jancic, C., Hugues, S., Guermonprez, P., Vargas, P., Cruz Moura, I., Lennon-Duménil, A. M. et al., Critical role for the NADPH oxidase NOX2 in the control of phagosomal pH and of antigen cross presentation in dendritic cells. Cell 2006. 126: 205-218.
30. Jancic, C., Savina, A., Wasmeier, C., Tolmachava, T., El-Benna, J., Dang, P. M., PascoIo, S. et al., Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat. Cell Biol. 2007. 9: 367-378.
31. Kovacsovics-Bankowski, M. and Rock,. K. L., A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995. 267: 243-246.
32. Ackerman, A. L., Kyritsis, C., Tampe, R. and Cresswell, P., Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Nad. Acad. Sci. USA 2003. 100: 12889-12894.
33. Kleijmeer, M. J., Escola, J. M., UytdeHaag, P. G., Jakobson, E., Griffith, J. M., Osterhaus, A. D., Stoorvogel, W. et al., Antigen loading of MHC class I molecules in the endocytic tract. Traffic 2001. 2: 124-137.
34. + T cells in vivo: The key to rational vaccine design. Annu. Rev. Immunol. 2005. 123: 651-682.
35. Albert, M. L., Sauter, B. and Bhardwaj, N., Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998. 392 86-89.
36. Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E. M., Nouri-Shirazi, M., Taquet, N., Rimoldi, D. et al., Cross-priming of naive, CD81T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 2000. 192: 1535-1544.
37. Ackerman, A. L., Giodini, A. and Cresswell, P., A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 2006. 25: 607-617.
38. Prato, S., Maxwell,, T., Pinzon-Charry, A., Schmidt, C. W., Corradin, G. and Lopez, J. A., MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide. Eur. J. Immunol. 2005. 35: 681-689.
39. Dufour, E., Carcelain, G., Gaudin, C., Flament, C., Avril, M. F. and Faure, F., Diversity of the cytotoxic melanoma-specific immune response: Some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J. Immunol. 1997. 158: 3787-3795.
40. Reis e Sousa, C., Dendritic cells in a mature age. Nat. Rev. Immunol. 2006. 6: 476-483.
41. Sallusto, F. and Lanzavecchia, A., Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulo-cyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha. J. Exp. Med. 1994. 179: 1109-1118.
42. Chapatte, L., Servis, C., Valmori D., Burlet-Schiltz, O., Dayer, J., Monsarrat, B., Romero, P. and Levy, F., Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells. J. Immunol. 2004. 173: 6033-6040.
43. Chapiro, J., Claverol, S., Piette, F. M. W., Stroobant, V., Guillaume, B., Gairin, J. E., Morel, S. et al., Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 2006. 176: 1053-1061.
44. Cisco, R. M., Abdel-Wahab, Z., Dannull, J., Nair, S., Tyler, D. S., Gilboa, E., Vieweg, J. et al., Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J. Immunol. 2004. 172: 7162-7168.
45. Matta, I., Andre, F., Lim, A., Tartaglia, J., Cox, W. I., Zitvogel, L., Angevin, E. and Kourilsky, P., Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J. Immunol. 2001. 167: 1795-1802.
46. Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C. et al., Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001. 7: 297-303.
47. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J. L. et al., Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 1998. 188: 1641-1650.
48. Zippelius, A., Batard, P., Rubio-Godoy, V., Bioley, G., Lienard, D., Lejeune, F., Rimoldi, D. et al., Effector function of human tumor-specific CD8T cell in melanoma lesions: A state of local functional tolerance. Cancer Res. 2004. 64: 2865-2873.
49. Rosenberg, S. A., Yang, J.C. and Restifo, N. P., Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004. 10: 909-915.
50. Phan, G. O., Touloukian, C. E., Yang, J. C., Restifo, N. P., Sherry, R. M., Hwu, P., Topalian, S. L. et al., Immunization of patients with metastatic melanoma using both class I- and class II- restricted peptides from melanoma-associated antigens. J. Immunother. (1997) 2003. 26: 349-356.
51. + T cell responses to vaccination with peptide IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005: 115: 739-746.
52. Zwaveling, S., Ferreira Mota, S. C., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H. and Melief, C. J., Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 2002. 169: 350-358.
53. + CTL in vivo with peptide vaccine constructs. J. Immunol. 1994. 152: 549-556.
54. Bijker, M. S., van den Eeden, S J., Franken, K. L., Melief, C. J., van der Burg, S. H. and Offringa, R., Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 2008. 38: 1033-1042.
55. Bioley, G., Jandus, C., Tuyaerts, S., Rimoldi, D., Kwok, W. W., Speiser, D. E., Tiercy, J. M. et al., Melan-A/MART-1-specific CD4T cells in melanoma patients: Identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J. Immunol. 2006. 177: 6769-6779.
56. Prlic, M., Williams, M. A. and Bevan, M. J., Requirements for CD8 T-cell priming, memory generation and maintenance. Curr. Opin. Immunol. 2007. 19: 315-319.
57. Burgdorf, S., Kautz, A., Bohnert. V., Knolle, P. A. and Kurts, C., Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8T cell activation. Science 2007. 316: 612-616.
58. Lakadamyali, M., Rust, M. J. and Zhuang, X., Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell 2006. 124: 997-1009.
59. Burgdorf, S. and Kurts, C., Endocytosis mechanisms and the cell biology of antigen presentation. Curr. Opin. Immunol. 2008. 20: 89-95.
60. Nagorsen, D., Servis, C., Levy, N., Provenzano, M., Dudley, M. E., Marincola, F. M. and Levy, F., Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210lM. Cancer Immunol. Immunother. 2004. 53: 817-824.
61. Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., Van Endert, P. and Amigorena, S., ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003. 425: 397-402.
62. + T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 2003. 281: 65-78.